Kevin Simpson new VP Gambro BCT and General Manager of its PET project

Kevin Simpson new Vice President, Gambro BCT and General Manager of its Pathogen Eradication Technology Project Stockholm, Sweden, June 7, 2001 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Gambro BCT has appointed Kevin Simpson as Vice President, Gambro BCT, and General Manager of its Pathogen Eradication Technology project. In this new role, Mr. Simpson will lead the worldwide Pathogen Eradication Technology project development and commercialization. He will join the company on June 11, 2001. Gambro BCT is on the forefront of exploration in the pathogen inactivation field. Pathogen inactivation seeks to eliminate known and unknown viruses and bacteria from blood products for transfusion. To this end, Gambro BCT's Pathogen Eradication Technology will help ensure the safety of the world's blood supply. This unique technology is the first single pathogen inactivation process to address all three major blood components - platelets, plasma and red blood cells. The pathogen inactivation process uses a natural chemical reaction between Riboflavin (Vitamin B2) and light to inactivate pathogens in blood products. Kevin Simpson previously was with Breakaway Solutions, a management consultant and strategy group providing business development, methodology, and implementation of B2B web initiatives for a variety of industries including medical technology and healthcare. Mr. Simpson served as President and CEO of Thermo Tech Ventures, which provided consulting services for emerging growth companies. Kevin Simpson gained his blood banking experience and knowledge at Haemonetics, where he was Vice President of the Commercial Plasma Group, responsible for the global P&L, sales, marketing, operations, engineering, quality, and customer service. Mr. Simpson earned a Bachelor of Science degree in Mechanical Engineering from Purdue University and a Master in Business Administration degree from Harvard Business School. "We are extremely excited to have Kevin leading over 30 scientists and engineers working on our Pathogen Eradication Technology project. He has extensive experience and knowledge of the medical technology, healthcare, and blood banking industries. Bringing Kevin's leadership to the Pathogen Eradication Technology project demonstrates Gambro's commitment to delivering natural, safe pathogen inactivation to the worldwide blood market," says David Perez, President of Gambro BCT. For further information please contact: David Perez, President Gambro BCT, tel. +1 303 232 68 00 Bengt Modéer, Investor Relations, tel. +46-8-613 65 00, +46-70-513 65 33 Karin Avasalu, Corporate Communications, tel. +46-8-613 65 00, +46-70- 513 65 99 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download:

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.